tiprankstipranks
Advertisement
Advertisement
Black Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data
PremiumCompany AnnouncementsBlack Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data
3M ago
Analyst Reiterates Buy on Black Diamond Therapeutics, Citing Differentiated EGFR Inhibitor and Strong Cash Runway Through 2028
Premium
Ratings
Analyst Reiterates Buy on Black Diamond Therapeutics, Citing Differentiated EGFR Inhibitor and Strong Cash Runway Through 2028
4M ago
Black Diamond price target raised to $11 from $10 at H.C. Wainwright
Premium
The Fly
Black Diamond price target raised to $11 from $10 at H.C. Wainwright
4M ago
Black Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer
PremiumCompany AnnouncementsBlack Diamond Advances Silevertinib Combo Into Phase 2 for Hard‑to‑Treat Brain Cancer
8M ago
3 Low P/E Ratio Stocks Poised to Surge Over 100% in 2026
Premium
Market News
3 Low P/E Ratio Stocks Poised to Surge Over 100% in 2026
8M ago
Promising Phase 2 Trial Results and Strategic Partnerships Support Buy Rating for Black Diamond Therapeutics
Premium
Ratings
Promising Phase 2 Trial Results and Strategic Partnerships Support Buy Rating for Black Diamond Therapeutics
9M ago
Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib
PremiumThe FlyBlack Diamond Therapeutics announces data from Phase 2 trial of silevertinib
9M ago
Black Diamond Therapeutics assumed with an Overweight at Piper Sandler
Premium
The Fly
Black Diamond Therapeutics assumed with an Overweight at Piper Sandler
9M ago
Black Diamond Therapeutics files $500M mixed securities shelf
Premium
The Fly
Black Diamond Therapeutics files $500M mixed securities shelf
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100